Skip to main content
Premium Trial:

Request an Annual Quote

Roche Gets FDA OK for Four Specimen Types in CT/NG Testing

NEW YORK (GenomeWeb News) – Roche announced today that the US Food and Drug Administration has granted 510(k) clearance for four additional specimen types for use with the firm's cobas CT/NG v2.0 test, which helps physicians diagnose Chlamydia trachomatis and Neisseria gonorrhoeae infections in symptomatic and asymptomatic patients.

The test can now be used with endocervical and clinician-collected vaginal specimens, female urine specimens collected in cobas PCR media, and cervical specimens collected in PreservCyt solution. The test already is used with self-collected vaginal swabs and male urine specimens.

The FDA first cleared the cobas CT/NG test in early 2012.

"With the addition of these specimen types, the cobas CT/NG v2.0 Test now provides US labs with a comprehensive offering for chlamydia and gonorrhea testing," Paul Brown, head of Roche Molecular Diagnostics, said in a statement. "This will enable more labs running the cobas 4800 System to combine CT/NG and HPV testing onto a single automated platform and further optimize their workflow."

The cobas HPV test was initially cleared for marketing by the FDA in April 2011, with a new workflow on the cobas system approved by the agency this past June.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.